Last $4.36 USD
Change Today -0.13 / -2.90%
Volume 384.1K
NEO On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

neogenomics inc (NEO) Snapshot

Open
$4.50
Previous Close
$4.49
Day High
$4.54
Day Low
$4.34
52 Week High
09/10/14 - $6.10
52 Week Low
04/15/14 - $2.95
Market Cap
261.5M
Average Volume 10 Days
220.4K
EPS TTM
$0.02
Shares Outstanding
60.0M
EX-Date
--
P/E TM
199.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOGENOMICS INC (NEO)

Related News

No related news articles were found.

neogenomics inc (NEO) Related Businessweek News

No Related Businessweek News Found

neogenomics inc (NEO) Details

NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

315 Employees
Last Reported Date: 05/8/14
Founded in 2001

neogenomics inc (NEO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $557.0K
Chief Financial Officer
Total Annual Compensation: $305.5K
Chief Medical Officer and Director of Researc...
Total Annual Compensation: $92.5K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $72.5K
Compensation as of Fiscal Year 2013.

neogenomics inc (NEO) Key Developments

Neogenomics Inc. Appoints Crowe Horwath LLP as Independent Registered Public Accounting Firm for the Fiscal Year of 2014

The Audit Committee of the Board of Directors of Neogenomics Inc. has completed a competitive process to review the appointment of the company's independent registered public accounting firm for the 2014 fiscal year. As a result of this process, effective November 12, 2014, the company engaged Crowe Horwath LLP as the company's independent registered public accounting firm.

Neogenomics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Fourth Quarter and Full Year of 2014

Neogenomics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company has posted net revenue of $23,217,000 against $16,884,000 a year ago. Loss from operations was $73,000 against profit from operations was $1,160,000 a year ago. LBIT was $291,000 against EBIT of $929,000 a year ago. Net loss was $291,000 or $0.01 basic and diluted per share against net profit of $900,000 or $0.02 basic and diluted per share a year ago. EBITDA was $1,608,000 against $2,279,000 a year ago. Adjusted EBITDA (Non-GAAP) was $2,636,000 against $2,163,000 a year ago. Purchase of property, plant and equipment was $2.2 million. Purchase of capital expenditures was $755,000. Excluding non-recurring expenses, net income would have been approximately $280,000 or $0.01 per share. For the nine months, the company has posted net revenue of $62,070,000 against $48,144,000 a year ago. Profit from operations was $899,000 against profit from operations was $1,971,000 a year ago. EBIT was $163,000 against EBIT of $1,222,000 a year ago. Net profit was $85,000 or $0.00 basic and diluted per share against net profit of $1,176,000 or $0.02 basic and diluted per share a year ago. Net cash provided by operating activities was $8,464,000 against $2,732,000 a year ago. EBITDA was $5,094,000 against $5,253,000 a year ago. Adjusted EBITDA (Non-GAAP) was $6,403,000 against $5,783,000 a year ago. The company achieved positive free cash flow. For the fourth quarter of 2014, the company expects revenue of $23.0 million- $24.5 million and net income of $0.00 to $0.01 per share. The company expects its gross margin to be in the 47% to 49% area. For the year 2014, the company expects to achieve $85.0 million to $86.5 million of revenue and earnings of $0.01 to $0.03 per share. This guidance is based on organic growth in the current business, and excludes any future acquisitions. The company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan.

Neogenomics Inc. Appoints Bruce Crowther as Member of the Board

On October 22, 2014, the board of directors of NeoGenomics Inc. appointed Bruce Crowther to serve as a member of the Board effective immediately, filling a vacancy created by an increase in the size of the Board from six to seven. It is expected that Mr. Crowther will serve on the Board's audit committee and compliance committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $4.36 USD -0.13

NEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $5.84 USD +0.22
Foundation Medicine Inc $22.43 USD -1.11
Genomic Health Inc $33.17 USD +0.74
Response Genetics Inc $0.55 USD +0.03
Rosetta Genomics Ltd $2.53 USD +0.15
View Industry Companies
 

Industry Analysis

NEO

Industry Average

Valuation NEO Industry Range
Price/Earnings 100.0x
Price/Sales 3.1x
Price/Book 4.6x
Price/Cash Flow 290.3x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit www.neogenomics.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.